Ref: Bio/Acts/ CS/ SE/ Ltrs- NSE/195

Biocon Limited - SEZ Developer
Biocon Special Economic Zone
Plot Nos. 2,3,4 & 5, Phase IV - B.I.A.
Bommasandra-Jigani Link Road
Bangalore 560 099, India
T 91 80 2808 2808
F 91 80 2852 3423

www.biocon.com

January 31, 2013

The National Stock Exchange of India Limited,
Exchange Plaza,
Bandra – Kurla Complex,
Bandra (East),
Mumbai- 400 051

"By Courier"

Kind Attn: Mr. Hari K.

Dear Sir,

Subject: Updation of the status regarding merger of wholly owned subsidiary

We refer to our letter dated 16 July, 2012, regarding matter to be considered by the Board on merger of Biocon Biopharmaceuticals Limited, a wholly owned subsidiary with the Company.

The Board of Directors of the Company, at its meeting held on July 25, 2012, had approved the Scheme of Amalgamation between Biocon Limited and Biocon Biopharmaceuticals Limited, a wholly owned subsidiary. The same has been intimated as part our quarterly un-audited results under Clause 41 vide our letter dated July 25, 2012.

Biocon Biopharmaceuticals Limited, a wholly owned subsidiary of the Company, has filed the application with Hon'ble High Court of Karnataka in September 2012 to summon for the directions to convene meeting under section 391 of the Companies Act, 1956 and the same has been dispensed by the Hon'ble High Court of Karnataka.

As both the Companies have their registered office in same state and the amalgamation related to merger of wholly owned subsidiary with the Company, Biocon Biopharmaceuticals Limited has only filed the application/petition before the Hon'ble High Court of Karnataka. Biocon Limited has not filed any separate application/petition in this regard.

Thereafter, the petition to sanction the Scheme of Amalgamation under section 391 to 394 has been filed before the Hon'ble High Court of Karnataka for the proposed merger and the petition came up for hearing on January 7, 2013, wherein Court had advised us to file the copy of the petition with the Regional Director of the region. The office of Regional Director has already issued its no objection to the said merger.

Since, the said merger of a subsidiary does not result in additional flow of consideration/issue of further shares, the matter relating to valuation of any assets/shares does not arise. Further as per the scheme filed, Biocon will take over the assets of wholly owned subsidiary at the book value. Pursuant to sanction of the Scheme of Amalgamation by the Hon'ble High Court the entire equity share capital of the Transferor Company shall stand cancelled.

We request you to take note of the above.

Thanking you,

Yours faithfully,
For Biocon Ltd,

Kiran Kumar G
Company Secretary
E: Kiran.Kumar@biocon.com
M: +91 9945315151
T: +91 80 2808 2037

By Fax to NSE: 022 – 2659 8237 / 38
By Email to NSE: cmlist@nse.co.in

Encl: Scheme of Amalgamation